Vertaling van "were very pleased with both " (Nederlands → Frans) :

Those who had taken part in this study were very pleased with both the form and the content of their training.
Les participants qui ont pris part à cette étude étaient très satisfaits de la forme et du contenu de la formation qu’ils ont suivie.

53 percent of AD caregivers surveyed who said they were not very involved (somewhat or not at all involved) in these interactions were dissatisfied with their loved one’s treatment, as compared with 31 percent who said they were engaged
· 53 percent of AD caregivers surveyed who sa id they were not very involved (somewhat or not at all involved) in these interactions were dissatisfied with their loved one’s treatment, as compared with 31 percent who said they were engaged

In these cases, these beverages were either consumed in very high quantities (1 420 ml) or whilst engaging in physical activity, or, what is more frequent, they were used in combination with alcohol.
Dans ces cas, celles-ci avaient été consommées, soit en très grande quantité (1.420 ml), soit à l’occasion d’une activité physique, ou plus fréquemment avec de l’alcool.

It follows that they were formulated with the intent of being realistic and pragmatic, an aim in which the composition of the working group itself played a part, as it involved both experts from the academic world and “field” experts.
Elles ont donc été élaborées dans un esprit de réalisme et de pragmatisme. La composition même du groupe de travail y a contribué, réunissant à la fois des experts provenant des milieux académiques et des experts de « terrain ».

The operating income margin of 31.9% of net sales was impacted by an impairment charge in R&D of USD 152 million after discontinuation of PTZ601, an anti-infective development project, while an asset write-up in Cost of Goods Sold of USD 100 million and an exceptional settlement gain in Other Income of USD 42 million were both related to the recent settlement with Teva regarding Famvir.
La marge opérationnelle de 31,9% du chiffre d’affaires net a été impactée par une charge d’un montant d’USD 152 millions pour perte de valeur en R&D après l’interruption du projet PTZ601 – un antiinfectieux en cours de développement – par la réévaluation d’un actif à hauteur d'USD 100 millions dans le coût des ventes et par un gain exceptionnel d’USD 42 millions dans les autres produits, tous deux liés au règlement conclu récemment avec Teva concernant Famvir.